|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
Strategic acquisitions
|
|
gptkbp:advocacy
|
Engagement with patient advocacy groups
|
|
gptkbp:allies
|
Formed with Industry Leaders
|
|
gptkbp:awards
|
Best Tech Company 2020
Industry recognition awards
|
|
gptkbp:benefits
|
Comprehensive Package
|
|
gptkbp:brand_recognition
|
gptkb:High
|
|
gptkbp:business_model
|
Service-Based
Biopharmaceutical model
|
|
gptkbp:ceo
|
gptkb:David_Cory
Eiger Group CEO
|
|
gptkbp:certification
|
gptkb:ISO_9001
|
|
gptkbp:client_acquisition_strategy
|
Targeted Marketing
|
|
gptkbp:client_base
|
SMEs and Enterprises
|
|
gptkbp:clinical_phase
|
Phase 2 and Phase 3 trials
|
|
gptkbp:clinical_trial
|
Ongoing
Conducts clinical research.
Published clinical data
|
|
gptkbp:collaborations
|
Academic institutions
|
|
gptkbp:community_engagement
|
Tech Education Programs
Health awareness initiatives
|
|
gptkbp:community_support
|
Local Initiatives
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._John_Doe
|
|
gptkbp:conflict
|
Addressed Proactively
|
|
gptkbp:cultural_diversity
|
Promoted
|
|
gptkbp:customer_satisfaction
|
gptkb:High
|
|
gptkbp:customer_support
|
24/7 Availability
|
|
gptkbp:data_security_measures
|
Robust
|
|
gptkbp:employees
|
100-200
Approximately 50
|
|
gptkbp:expansion_plans
|
New Markets
|
|
gptkbp:feedback
|
Regular Surveys
|
|
gptkbp:financial_performance
|
gptkb:Strong
|
|
gptkbp:financials
|
gptkb:public_company
gptkb:stable
Venture Capital Firms
|
|
gptkbp:focus
|
Rare diseases
|
|
gptkbp:founded
|
gptkb:1997
gptkb:2000
|
|
gptkbp:founder
|
gptkb:Dr._Rainer_Schmid
Eiger Group Founders
|
|
gptkbp:funding
|
Secured research funding
|
|
gptkbp:global_presence
|
International operations
|
|
gptkbp:has_advisory_board
|
Established advisory board
|
|
gptkbp:has_culture
|
Innovative and Collaborative
|
|
gptkbp:headquarters
|
gptkb:Singapore
gptkb:Switzerland
|
|
gptkbp:hosts_events
|
Tech Conferences
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eiger Group
|
|
gptkbp:industry
|
gptkb:technology
Pharmaceuticals
|
|
gptkbp:innovation
|
Core Focus
|
|
gptkbp:instruction_set
|
Multiple drug candidates
|
|
gptkbp:invention
|
Multiple patents filed
|
|
gptkbp:investment
|
Institutional investors
Venture capital funding
Prioritized
Active investor relations program
|
|
gptkbp:investment_focus
|
Global market
B2 B Technology
|
|
gptkbp:investment_in_tech
|
gptkb:Significant
|
|
gptkbp:key_people
|
Eiger Group Executives
|
|
gptkbp:leadership
|
Recognized
|
|
gptkbp:location
|
Asia-Pacific Region
|
|
gptkbp:market
|
Ongoing
|
|
gptkbp:market_launch
|
gptkb:Regular
New product launches
|
|
gptkbp:market_position
|
Leading Tech Company
|
|
gptkbp:market_share
|
Growing
|
|
gptkbp:marketing_strategy
|
Growth-Oriented
Innovative market strategies
|
|
gptkbp:mission
|
Innovate Technology Solutions
To develop therapies for rare diseases.
|
|
gptkbp:network
|
Active Participation
|
|
gptkbp:parent_company
|
gptkb:Eiger_Holdings
|
|
gptkbp:partnership
|
Global Tech Firms
Established with Key Players
|
|
gptkbp:partnerships
|
Local Universities
Various Tech Companies
Collaborative partnerships
Various biotech companies
Partnerships with clinical research organizations
|
|
gptkbp:product
|
Agile Methodology
|
|
gptkbp:products
|
gptkb:Software_Solutions
Eiger's antiviral therapies
|
|
gptkbp:publications
|
Published research articles
|
|
gptkbp:region
|
gptkb:Asia
|
|
gptkbp:regulatory_compliance
|
FDA approved products
Meets regulatory standards
|
|
gptkbp:research_and_development
|
Active
Innovative therapies
|
|
gptkbp:research_areas
|
Infectious diseases
|
|
gptkbp:research_focus
|
Antiviral therapies
|
|
gptkbp:revenue
|
10 million USD
Reported revenue in millions
15% per year
|
|
gptkbp:scientific_instruments
|
gptkb:Eiger_Innovation_Hub
|
|
gptkbp:services
|
gptkb:Consulting_Services
Clinical development
|
|
gptkbp:social_media
|
gptkb:Linked_In
|
|
gptkbp:social_responsibility
|
Active Programs
|
|
gptkbp:specialization
|
gptkb:cloud_computing
|
|
gptkbp:stock_symbol
|
EIGR
|
|
gptkbp:strategic_goals
|
Expand Internationally
Expand product portfolio
|
|
gptkbp:student_enrollment
|
gptkb:Strong
Above Average
|
|
gptkbp:subsidiaries
|
gptkb:Eiger_Solutions
|
|
gptkbp:sustainability
|
Commitment to sustainable practices
|
|
gptkbp:sustainability_initiatives
|
gptkb:Green_Technology_Solutions
|
|
gptkbp:team
|
Experienced executives
|
|
gptkbp:technology_stack
|
Cloud and AI
|
|
gptkbp:testimonials
|
Positive Feedback
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:trademark
|
gptkb:Eiger_Brand
|
|
gptkbp:training
|
Continuous Development Programs
|
|
gptkbp:treatment
|
Positive clinical outcomes
|
|
gptkbp:trends
|
Monitored
|
|
gptkbp:type_of_business
|
Established
|
|
gptkbp:user_engagement
|
gptkb:High_Level
|
|
gptkbp:uses_technology
|
Rapid
|
|
gptkbp:vision
|
Empower Businesses with Technology
|
|
gptkbp:website
|
www.eigerbio.com
www.eigergroup.com
|
|
gptkbp:work_location
|
Flexible and Remote Options
|
|
gptkbp:bfsParent
|
gptkb:Hotel_Eiger
|
|
gptkbp:bfsLayer
|
9
|